For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Score ...

Core Insights - Illumina's international revenue performance is crucial for assessing its financial resilience and growth prospects [1][2] - The company's reliance on international markets is increasingly important for understanding its earnings sustainability and growth potential [2][3] Revenue Performance - Illumina's total revenue for the quarter ending September 2024 was $1.08 billion, a decline of 3.5% year over year [4] - Europe contributed $291 million, accounting for 26.94% of total revenue, with a surprise decline of -4.03% compared to analyst expectations [5] - Asia-Pacific, Middle East, and Africa generated $105 million, representing 9.72% of total revenue, with a surprise decline of -12.03% [6] - Greater China contributed $75 million, making up 6.94% of total revenue, with a surprise decline of -4.98% [7] Future Revenue Expectations - Analysts expect Illumina to report $1.07 billion in total revenue for the current fiscal quarter, indicating a decline of 4.7% from the previous year [8] - For the full year, total revenue is projected to be $4.31 billion, a decrease of 4.2% from last year, with regional contributions expected from Europe (27.6%), Asia-Pacific, Middle East, and Africa (11%), and Greater China (7.3%) [9] Strategic Considerations - Illumina's international market presence offers both opportunities and challenges, necessitating close monitoring of revenue trends to project future directions [10] - Analysts consider various factors, including a company's domestic standing, when adjusting earnings forecasts [11]

SAN DIEGO, Nov. 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: Wolfe Research 2024 Healthcare Conference on November 20, 2024Fireside chat at 6:20am Pacific Time (9:20am Eastern Time) 7th Annual Evercore HealthCONx Conference on December 3, 2024Fireside chat at 10:20am Pacific Time (1:20pm Eastern Time)For each conference, the webcast can be accessed through the Investor Info section of Illumina's website at i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 29, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-35406 Illumina, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0804655 (State or other jurisdiction of incorporat ...

With the Grail carve-out behind it, Illumina, Inc.'s (NASDAQ: ILMN ) financials are rebounding, helping the stock sentiment. That's not all; a second phase of re-rating should come from a top-line re-acceleration from 2025 to 2027 as delayed and elongated CAPEX cyclesHello readers! Passionate about technology, my focus will be on finding and analyzing companies that can play a relevant role in today's geopolitics, leverage their IP, and eventually, with time, become new leaders. Therefore, the investment st ...

Illumina Inc. (ILMN) reported third-quarter 2024 adjusted earnings per share (EPS) of $1.14, which beat the Zacks Consensus Estimate of 87 cents by a stupendous 31.0%. The bottom line was above the year-ago figure of 33 cents.The adjustments exclude the impact of GRAIL’s pre-acquisition net operating losses on GILTI, the utilization of U.S. foreign tax credits, and the Pillar Two global minimum top-up tax, which became effective from the first quarter of 2024.Including one-time items, the company’s GAAP EPS ...

Illumina (ILMN) reported $1.08 billion in revenue for the quarter ended September 2024, representing a year-over-year decline of 3.5%. EPS of $1.14 for the same period compares to $0.33 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.07 billion, representing a surprise of +0.48%. The company delivered an EPS surprise of +31.03%, with the consensus EPS estimate being $0.87.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stre ...

Financial Data and Key Metrics - Revenue for Q3 2024 was $1.1 billion, in line with expectations [10] - Non-GAAP operating margin was 22.6%, and diluted earnings per share were $1.14, exceeding expectations [12] - Revenue in the Americas was down 6% YoY, Europe was up 12%, EMEA was up 7%, and Greater China was down 23% [10] - The company placed an additional 58 NovaSeq X Plus instruments, bringing the total installed base to 527, with 40% shipped to clinical customers [11] - The X-Series surpassed $1 billion in cumulative revenue [11] Business Line Data and Key Metrics - Sequencing consumables revenue was $741 million, up 7% YoY, driven by strong uptake in X consumables [29] - Sequencing instruments revenue was $104 million, a 42% YoY decline, slightly behind expectations [31] - Sequencing service and other revenue was $150 million, up 6% YoY, driven by strategic partnerships and high instrument service contract revenue [33] - More than 55% of high-throughput gigabases sequenced and over 35% of high-throughput consumables revenue were on the NovaSeq X series [29] Market Data and Key Metrics - Total sequencing GB output on connected high and mid-throughput instruments grew over 40% YoY, with robust growth from both clinical and research customers [31] - The company expects almost half of high-throughput consumables revenue to transition to the X series by mid-2025 [30] Company Strategy and Industry Competition - The company aims to drive high single-digit revenue growth and 500 basis points of operating margin expansion by 2027, with annual EPS growth in the double-digits to teens over the next three years [14] - Key priorities include deeper customer collaboration, continuous innovation, and operational excellence [15] - The company recently launched the MiSeq i100, addressing demand for flexible solutions for smaller-scale projects with faster turnaround times [19] - The company is developing comprehensive whole genome sequencing and the five-phase genome, which will launch over the next 12 to 18 months [21] Management Commentary on Operating Environment and Future Outlook - The near-term macroeconomic environment remains constrained, and the company expects 2024 revenue growth to be slightly lower than prior guidance [13] - The company is raising guidance for 2024 operating margin and earnings per share, reflecting progress in operational excellence and margin expansion [13] - The company expects to return to growth in 2025, with high single-digit revenue growth by 2027 [49] Other Important Information - The company divested GRAIL in June 2024, and all financial information discussed excludes GRAIL [5][27] - The company issued $500 million in debt at a 4.65% coupon to redeem a high-cost $750 million delayed broad term loan, reducing leverage and interest rates [38] - The company repurchased 770,000 shares for $98 million at an average price of $127.71 per share [41] Q&A Session Summary Question: Guidance and Clinical Transition Concerns [50] - The company does not foresee a "clinical cliff" for consumable revenue, as the transition to the X series is gradual, typically taking 12-18 months [52][55] - Q4 consumables guidance assumes a typical seasonal decline due to fewer working days and holidays [56][57] Question: Mid-Throughput Decline and 2025 Outlook [59] - The mid-throughput decline was driven by macroeconomic pressures and competition, particularly in the U.S. and Europe [60][61] - The company expects to return to positive growth in 2025, with high single-digit growth by 2027 [63] Question: Price per GB and Margin Expansion [65] - The price per GB impact was closer to 25%, within the expected range of 20-25% [67] - The company is targeting 500 basis points of margin expansion from a base of 21% [67][68] Question: NGS Consumable Revenue Growth [71] - Consumables revenue grew 7% in Q3, with both research and clinical segments showing strong growth [73] Question: Clinical X Transition and Pricing Dynamics [76] - The transition to the X series is driven by its benefits, including lower costs and improved workflows, with customers gradually moving assays over time [77][78] - Multi-year contracts are not instrument-specific and will continue with the X series [83] Question: Elasticity of Demand and Q4 Seasonality [85] - Customers are expanding assays and increasing sequencing depth, driving volume growth despite lower prices [89] - Q4 seasonality is expected to impact consumables due to fewer working days and inventory management [90][91] Question: Revenue Guidance Change [93] - The revenue guidance change is primarily due to slower deal closures in the instruments business, with the impact spread across instruments, consumables, and services [94][96] Question: Macro Environment and Growth Outlook [99] - The company sees consumables growth as a leading indicator of improvement, but the macroeconomic environment remains a headwind [100][101] Question: Margin Expansion and Cost Savings [103] - The company achieved $100 million in cost savings in 2024 and is targeting an additional $200 million, with a focus on COGS and operating expenses [107][108] Question: Free Cash Flow and Share Buybacks [112] - The company generated $284 million in free cash flow in Q3 and plans to continue share buybacks and tuck-in M&A to drive growth [113][117] Question: End Market Dynamics [120] - Europe showed steady growth, while the Americas faced tougher comparisons due to higher X instrument placements in the prior year [122] Question: Single-Cell Opportunity [124] - The acquisition of Fluent BioSciences expands the single-cell market opportunity, with a focus on enabling large-scale experiments [125][126] Question: MiSeq i100 and XLEAP Impact [130] - The MiSeq i100 is expected to drive growth in the low-throughput segment, with significant interest from customers [131][133] - Over 60% of NextSeq 1K/2K users have adopted the XLEAP chemistry, showing strong market reception [135]

分组1 - Illumina reported quarterly earnings of $1.14 per share, exceeding the Zacks Consensus Estimate of $0.87 per share, and showing a significant increase from $0.33 per share a year ago, resulting in an earnings surprise of 31.03% [1] - The company achieved revenues of $1.08 billion for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 0.48%, although this represents a decline from year-ago revenues of $1.12 billion [2] - Illumina has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance in earnings [2] 分组2 - The stock has underperformed the market with a gain of about 7.6% since the beginning of the year, compared to the S&P 500's gain of 20.1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.93 on revenues of $1.1 billion, and for the current fiscal year, it is $3.62 on revenues of $4.34 billion [7] - The Medical - Biomedical and Genetics industry, to which Illumina belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8]

Financial Performance - Core Illumina revenue for Q3 2024 was $1.1 billion, down 2% from Q3 2023 on a constant currency basis[2] - Core Illumina GAAP operating margin for Q3 2024 was 68.6%, with a non-GAAP operating margin of 22.6%[2] - Core Illumina GAAP diluted EPS for Q3 2024 was $4.03, and non-GAAP diluted EPS was $1.14[2] - Fiscal year 2024 Core Illumina revenue guidance was lowered to a decline of ~3% from fiscal year 2023, with Q4 2024 revenue expected to be approximately $1.07 billion[2] - Fiscal year 2024 Core Illumina non-GAAP operating margin guidance was raised to a range of 21% to 21.5%[2] - Fiscal year 2024 Core Illumina non-GAAP diluted EPS guidance was raised to a range of $4.05 to $4.15[2] - Total revenue for Q3 2024 was $1.08 billion, a decrease of 4% compared to $1.119 billion in Q3 2023[20] - Net income for Q3 2024 was $705 million, compared to a net loss of $754 million in Q3 2023[20] - Core Illumina constant currency revenue for Q3 2024 was $1.078 billion, a decrease of 2% compared to $1.101 billion in Q3 2023[25] - Consolidated constant currency revenue for Q3 2024 was $1.078 billion, a decrease of 3% compared to $1.114 billion in Q3 2023[26] - Non-GAAP diluted earnings per share for the three months ended September 29, 2024, was $1.14, compared to GAAP diluted earnings per share of $4.03[28] - Non-GAAP net income for the three months ended September 29, 2024, was $181 million, compared to GAAP net income of $642 million[29] - Non-GAAP diluted earnings per share for the nine months ended September 29, 2024, was $3.20, compared to GAAP diluted earnings per share of $4.88[28] - Non-GAAP net income for the nine months ended September 29, 2024, was $510 million, compared to GAAP net income of $777 million[29] - Non-GAAP diluted earnings per share for the nine months ended October 1, 2023, was $0.73, compared to GAAP diluted loss per share of $(6.23)[31] - Non-GAAP net income for the nine months ended October 1, 2023, was $115 million, compared to GAAP net loss of $(986) million[32] - Non-GAAP gross profit for the consolidated operations was $732 million, representing 65.4% of revenue[34] - Non-GAAP operating profit for the consolidated operations was $93 million, representing 8.3% of revenue[34] - Core Illumina non-GAAP gross profit was $2.228 billion, representing 69.0% of revenue[36] - Consolidated non-GAAP operating profit was $362 million, or 11.1% of revenue[36] - Non-GAAP gross profit for Core Illumina is $2,208 million, representing 66.1% of revenue[38] - Non-GAAP operating profit for Core Illumina is $681 million, representing 20.4% of revenue[38] - Non-GAAP operating profit for Consolidated is $196 million, representing 5.8% of revenue[38] Expenses and Margins - Gross margin for Q3 2024 increased to 68.9% from 64.7% in Q3 2023, driven by cost savings and improved productivity[5] - Research and development expenses for Q3 2024 were $253 million, a decrease from $315 million in Q3 2023[20] - Selling, general and administrative expenses for Q3 2024 were $239 million, a decrease from $303 million in Q3 2023[20] - GAAP R&D expense for the consolidated operations was $315 million, accounting for 28.1% of revenue[34] - Non-GAAP R&D expense for the consolidated operations was $312 million, representing 27.8% of revenue[34] - GAAP SG&A expense for the consolidated operations was $303 million, accounting for 27.0% of revenue[34] - Non-GAAP SG&A expense for the consolidated operations was $328 million, representing 29.3% of revenue[34] - Non-GAAP R&D expense for Core Illumina is $754 million, representing 22.5% of revenue[38] - Non-GAAP SG&A expense for Core Illumina is $773 million, representing 23.1% of revenue[38] Cash Flow and Assets - Free cash flow for Q3 2024 was $284 million, compared to $94 million in the prior year period[7] - Free cash flow for Q3 2024 was $284 million, compared to $94 million in Q3 2023[23] - Total assets decreased to $6.014 billion as of September 29, 2024, from $10.111 billion as of December 31, 2023[17] - Stockholders' equity decreased to $2.125 billion as of September 29, 2024, from $5.745 billion as of December 31, 2023[18] - Cash and cash equivalents decreased to $869 million as of September 29, 2024, from $1.048 billion as of December 31, 2023[17] Legal and Tax Adjustments - Legal contingency and settlement adjustments reduced GAAP net income by $488 million for the three months ended September 29, 2024[29] - Goodwill and intangible impairment adjustments increased GAAP net income by $821 million for the nine months ended October 1, 2023[32] - GILTI, US foreign tax credits, and global minimum top-up tax adjustments increased non-GAAP net income by $54 million for the three months ended September 29, 2024[29] - Incremental non-GAAP tax expense reduced non-GAAP net income by $26 million for the three months ended September 29, 2024[29] - GAAP goodwill and intangible impairment for the consolidated operations was $821 million, accounting for 73.4% of revenue[34] - GAAP legal contingency and settlement was $(474) million, or (14.4)% of revenue[36] - Non-GAAP other expense was $(32) million, or (1.0)% of revenue[36] - Consolidated GAAP operating loss was $(1.008) billion, or (30.8)% of revenue[36] - Strategic investment related loss was $339 million, or 10.4% of revenue[36] - Goodwill and intangible impairment related to GRAIL is $821 million, representing 24.3% of revenue[38] - Legal contingency and settlement reversal for Q3 2024 is $14 million, representing 0.4% of revenue[38] Product and Innovation Updates - The company introduced the MiSeq i100 Series, Illumina's simplest and fastest benchtop sequencers[8] - The company announced plans to provide updates on key innovations in whole-genome sequencing, proteomics, and single-cell technology at the American Society of Human Genetics Annual Meeting[8] Other Financial Metrics - GAAP other expense, net for the consolidated operations was $(28) million, accounting for (2.6)% of revenue[34] - Non-GAAP other expense, net for the consolidated operations was $(6) million, representing (0.5)% of revenue[34] - Strategic investment-related loss, net for the consolidated operations was $19 million, accounting for 1.8% of revenue[34] - Core Illumina GAAP gross profit was $2.181 billion, or 67.6% of revenue[36] - Non-GAAP tax provision for Core Illumina is $48 million, representing 21.0% of revenue for the three months ended September 2024[43] - Non-GAAP tax provision for Consolidated is $48 million, representing 21.0% of revenue for the three months ended September 2024[44] - Non-GAAP tax provision for Consolidated is $77 million, representing 23.4% of revenue for the nine months ended September 2024[44]